"Using Data from Process Analytics as Part of an Overarching Control Strategy" with Martin Warman
The free webinar will take place on Wednesday, September 16, 2026, from 2:00–2:45 p.m. CEST (UTC+2) and will be held in English. After the expert presentation, participants will have the opportunity to ask their individual questions live during the interactive Q&A session.
Process Analytical Technology (PAT) is traditionally used to predict Critical Quality Attributes (CQAs) or to support Real-Time Release Testing. While these applications are well established, they often position PAT as a medium- or high-impact GMP method requiring extensive validation. As a result, the broader potential of process analytics is frequently overlooked.
In this webinar, you will discover how process analytics can be used as part of an overarching control strategy to ensure manufacturing processes remain in a state of control, rather than focusing solely on product quality prediction. You will learn how PAT data can support process improvement within an approved operating space, enabling greater process robustness, sustainability, and operational efficiency while supporting more effective GMP decision-making.
Moving beyond the traditional focus on Real-Time Release Testing, this session will provide a different perspective on how process analytics can be applied to maximize process understanding and long-term manufacturing performance.
This webinar is particularly relevant for professionals in:
Anyone involved in implementing, optimizing, or operating process analytical technologies and (pharmaceutical) manufacturing processes will benefit from the insights shared in this session.
Martin Warman is Director of Martin Warman Consultancy Ltd and has more than 30 years of experience in Process Analytical Technology (PAT) and pharmaceutical manufacturing. Throughout his career, he has held leading positions in industry, including at Pfizer and Vertex Pharmaceuticals, where he led PAT initiatives and contributed to the development of one of the first approved continuous manufacturing platforms incorporating Real-Time Release Testing.
Today, Martin advises global healthcare companies on the strategic implementation of PAT, supporting projects from early feasibility studies through regulatory approval and the development of long-term control strategies.
We look forward to your participation!
Your Hellma team